Why Policy Is Canada's Competitive Advantage in Pharmaceutical Manufacturing

Canada has the people, the expertise, and the manufacturing capacity to play an important role in the global pharmaceutical industry. The question is no longer whether Canada can manufacture medicines. The question is whether we are creating the conditions that encourage manufacturers to continue investing here.

Around the world, governments are recognizing that pharmaceutical manufacturing is about far more than producing medicines. It supports healthcare systems, strengthens economies, creates skilled jobs, and contributes to national resilience. As a result, many countries are adopting policies designed to attract investment, expand domestic production, and strengthen long-term competitiveness.

Canada has an opportunity to do the same.

Manufacturing Decisions Begin Long Before Production

When pharmaceutical companies decide where to manufacture, they consider far more than the availability of facilities or a skilled workforce.

They look at regulatory predictability, tax policy, market stability, procurement practices, trade relationships, and the overall investment climate. Together, these factors influence where capital is invested, where production takes place, and where jobs are created.

In an increasingly competitive global environment, countries are actively using these policy tools to attract and retain pharmaceutical manufacturing. Canada must ensure it remains an attractive place to invest.

Building on Canada's Existing Strengths

Canada is not starting from scratch. Canadian generic and contract pharmaceutical manufacturers already operate sophisticated facilities that produce medicines used every day by Canadians. The sector supports high-quality employment, contributes to regional economies, and forms an important part of Canada's healthcare infrastructure.

These strengths provide a solid foundation for future growth.

The next step is creating an environment that gives manufacturers confidence to continue expanding their operations in Canada. Predictable regulatory pathways, competitive tax policies, strategic procurement practices, and long-term policy certainty all contribute to that confidence.

 

A Strategic Opportunity

Recent developments around the world, including renewed industrial policies and growing competition for pharmaceutical investment, demonstrate that governments increasingly view pharmaceutical manufacturing as a strategic asset.

For Canada, this represents an opportunity rather than simply a challenge.

By creating policies that encourage investment and support domestic manufacturing, Canada can strengthen its pharmaceutical sector while reinforcing healthcare resilience, economic growth, and long-term competitiveness.

Looking Ahead

Strong pharmaceutical manufacturing does not happen by accident. It is built through thoughtful policy, collaboration between industry and government, and a long-term commitment to competitiveness.

Canada already has many of the ingredients needed for success. The opportunity now is to build on those strengths with policies that support Canadian generic and contract manufacturers and encourage continued investment in domestic production.

The Canadian Pharmaceutical Manufacturers and Exporters Alliance (CPMEA) believes that a competitive policy environment is essential to strengthening Canada's pharmaceutical manufacturing sector. By supporting domestic manufacturers today, Canada can build a stronger, more resilient healthcare system and a more competitive economy for the future.

Learn more at www.cpmea.ca.

---

The Canadian Pharmaceutical Manufacturers and Exporters Alliance (CPMEA) – Alliance fabricants et exportateurs pharmaceutiques du Canada (AFEPC) represents pharmaceutical companies that manufacture in Canada. We have come together in an Alliance to tell the story of drug production in Canada and to raise awareness of the unique issues facing our industry.

Click here to contact us, or email us directly at info@cpmea.ca.